Cargando…

Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study

BACKGROUND AND PURPOSE: Despite the availability of risk engines to determine cardiovascular risk, risk factor control is suboptimal. Using EURIKA data we compared risk factor control in Germany with that of 11 other European countries (rest of Europe [ROE]) to identify differences and opportunities...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmieder, Roland E, Goebel, Matthias, Bramlage, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333468/ https://www.ncbi.nlm.nih.gov/pubmed/22536072 http://dx.doi.org/10.2147/VHRM.S29915

Ejemplares similares

Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA)
por: Rodríguez-Artalejo, Fernando, et al.
Publicado: (2010)

C-reactive protein levels in patients at cardiovascular risk: EURIKA study
por: Halcox, Julian PJ, et al.
Publicado: (2014)

Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study
por: Banegas, José R., et al.
Publicado: (2011)

Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study
por: Guallar, Eliseo, et al.
Publicado: (2011)

Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study
por: Halcox, Julian P., et al.
Publicado: (2017)

Risk classification in primary prevention of CVD according to QRISK2 and JBS3 ‘heart age’, and prevalence of elevated high-sensitivity C reactive protein in the UK cohort of the EURIKA study
por: Johns, Ieuan, et al.
Publicado: (2018)

Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice
por: Schmieder, Roland E, et al.
Publicado: (2009)

The Effect of Resting Heart Rate on the New Onset of Microalbuminuria in Patients With Type 2 Diabetes: A Subanalysis of the ROADMAP Study
por: Schmieder, Roland E., et al.
Publicado: (2016)

Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE
por: Gitt, Anselm K, et al.
Publicado: (2012)

Achievement of individualized treatment targets in patients with comorbid type-2 diabetes and hypertension: 6 months results of the DIALOGUE registry
por: Schmieder, Roland E, et al.
Publicado: (2015)

Safety, tolerability, and efficacy of a fixed-dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5/25 mg in daily practice
por: Bramlage, Peter, et al.
Publicado: (2013)

Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice
por: Bramlage, Peter, et al.
Publicado: (2014)

A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation
por: Ott, Christian, et al.
Publicado: (2017)

Heat in Germany: Health risks and preventive measures
por: Winklmayr, Claudia, et al.
Publicado: (2023)

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
por: Bramlage, Peter, et al.
Publicado: (2010)

Cardiovascular risk reduction by reversing endothelial dysfunction:ARBs, ACE inhibitors, or both? Expectations from The ONTARGET Trial Programme
por: Ruilope, Luis Miguel, et al.
Publicado: (2007)

Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Evaluating an implementation strategy in cardiovascular prevention to improve prescribing of statins in Germany: an intention to treat analysis
por: Keller, Heidemarie, et al.
Publicado: (2013)

The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
por: Bramlage, Peter, et al.
Publicado: (2015)

EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry
por: Gitt, Anselm K, et al.
Publicado: (2013)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Access Barriers to Dental Treatment and Prevention for Turkish Migrants in Germany – A Qualitative Survey
por: Spinler, Kristin, et al.
Publicado: (2022)

Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine
por: Ott, Christian, et al.
Publicado: (2021)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
por: Kolwelter, Julie, et al.
Publicado: (2021)

Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension
por: Bramlage, Peter
Publicado: (2009)

Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID‐19 pandemic
por: Huang, Helen, et al.
Publicado: (2023)

Reduced rate of admissions for acute coronary syndromes during the COVID-19 pandemic: an observational analysis from a tertiary hospital in Germany
por: Vacanti, Gaetano, et al.
Publicado: (2020)

Editorial: Physical activity and exercise for the prevention and management of cardiovascular risk and cardiovascular disease
por: Volterrani, Maurizio, et al.
Publicado: (2023)

Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
por: Gitt, Anselm K., et al.
Publicado: (2016)

Knowledge of cardiovascular disease risk factors, practice, and barriers of community pharmacists on cardiovascular disease prevention in North West Ethiopia
por: Birarra, Mequanent Kassa, et al.
Publicado: (2022)

Patient-reported continuity of care and the association with patient experience of cardiovascular prevention: an observational study in Germany
por: Arnold, Christine, et al.
Publicado: (2022)

Patient and disease characteristics of adult patients with type 1 diabetes in Germany: an analysis of the DPV and DIVE databases
por: van Mark, Gesine, et al.
Publicado: (2019)

Abdominal obesity is associated with microalbuminuria and an elevated cardiovascular risk profile in patients with hypertension
por: Thoenes, Martin, et al.
Publicado: (2009)

Comprehensive Risk Management for the Prevention of Cerebro-Cardiovascular Diseases in Japan
Publicado: (2017)

Diabetes: how to manage cardiovascular risk in secondary prevention patients
por: Anderson, Sarah L, et al.
Publicado: (2022)

Global health education in Germany: an analysis of current capacity, needs and barriers
por: Kaffes, Ioannis, et al.
Publicado: (2016)

BARRIERS TO APPLYING FOR MEDICAL REHABILITATION: A TIME-TO-EVENT ANALYSIS OF EMPLOYEES WITH SEVERE BACK PAIN IN GERMANY
por: ZIMMER, Julia-Marie, et al.
Publicado: (2022)

Benefits, Barriers and Determinants of Clinical Pathway Use in Germany, Austria and Switzerland. A pilot study
por: Noehammer, Elisabeth, et al.
Publicado: (2022)

Effects of Single Pill Combinations Compared to Identical Multi Pill Therapy on Outcomes in Hypertension, Dyslipidemia and Secondary Cardiovascular Prevention: The START-Study
por: Wilke, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ji7iejk1kc2ts3nldmvjd2nanh